Cyclooxygenase-2 and survivin in superficial urothelial carcinoma of the bladder and correlation with intratumoural microvessel density

Journal of International Medical Research

Volumn 38, Issue 5, 2010, Pages 1689-1699

  Yildirim, U ^a   Erdem, H ^a   Kayikci, A ^a   Sahin, A F ^a   Uzunlar, A K ^a   Albayrak, A ^b  

^a DUZCE UNIVERSITY   (Turkey)

^b DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Cancer stage; Cyclooxyogenase 2(COX 2); Surviving; cancer grade; Urothelial carcinoma

Indexed keywords

CYCLOOXYGENASE 2; SURVIVIN;

ARTICLE; BLADDER CARCINOMA; BLOOD VESSEL PARAMETERS; CANCER GRADING; CANCER STAGING; CELL COUNT; CELL DENSITY; CONTROLLED STUDY; CORRELATION FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; MICROVESSEL DENSITY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; UROGENITAL TRACT CANCER;

EID: 78449266623     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800514     Document Type: Article

References (47)

1. Jameson C: The pathology of bladder cancer. In: Carcinoma of the Bladder (MacVicar D, ed). New York: Cambridge University Press, 2008: 1697 pp 1-23.
2. Margulis V, Lotan Y, Shariat S: Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008; 26: 59-65.
3. Schultz IJ, Witjes JA, Swinkels DW, et al: Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin. Clin Chim Acta 2006; 368: 20-32.
4. Choi YL, Lee SH, Kwon GY, et al: Overexpression of CD24 association with invasiveness in urothelial carcinoma of the bladder. Arch Pathol Lab Med 2007; 131: 275-281.
5. Gazzaniga P, Gradilone A, Giuliani L, et al: Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003; 14: 85-90.
6. Subbaramaiah K, Zakim D, Weksler BB, et al: Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med 1997; 216: 201-210.
7. Shirahama T, Arima J, Akiba S, et al: Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92: 188-193.
8. Friedrich MG, Toma MI, Petri S, et al: Cyclooxygenase-2 promotes angiogenesis in Pta/T1 urothelial bladder carcinoma but does not predict recurrence. BJU Int 2003; 92: 389-392.
9. Kömhoff M, Guan Y, Shappell HW, et al: Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000; 157: 29-35.
10. Pasricha PJ, Bedi A, O'Connor K, et al: The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-998.
11. Jones MK, Wang H, Peskar B, et al: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-1423.
12. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998; 90: 1609-1620.
13. Tatsuguchi A, Matsui K, Shinji Y, et al: Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol 2004; 35: 488-495.
14. Aoki T, Tsukinoki K, Karakida K, et al: Expression of cyclooxygenase-2, Bcl-2 and Ki-67 in pleomorphic adenoma with special reference to tumor proliferation and apoptosis. Oral Oncol 2004; 40: 954-959.
15. Adida C, Crotty PL, McGrath J, et al: Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998; 152: 43-49.
16. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
17. Altieri D: Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 2004; 92: 653-656.
18. Caldas H, Jiang Y, Holloway MP, et al: Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005; 24: 1994-2007.
19. Karam J A, Lotan Y, Ashfaq R, et al: Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 2007; 70: 482-486.
20. Yin W, Chen N, Zhang Y, et al: Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol 2006; 19: 1487-1497.
21. Barnes N, Haywood P, Flint P, et al: Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006; 94: 253-258.
22. Athanassiadou P, Grapsa D, Athanassiades P, et al: The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract 2008; 204: 241-249.
23. Krysan K, Merchant FH, Zhu L, et al: Cyclooxygenase-2-dependent expression of survivin in non-small cell lung cancer. FASEB J 2004; 18: 206-208.
24. Krysan K, Dalwadi H, Sharma S, et al: Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 2004; 64: 6359-6362.
25. Carpagnano GE, Spanevello A, Palladino GP, et al: Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: How hot is the link? Lung Cancer 2010; 67: 108-113.
26. Erkanli S, Bolat F, Kayaselcuk F, et al: COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol 2007; 104: 320-325.
27. Lambropoulou M, Papadopoulos N, Tripsianis G, et al: Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients. J Cancer Res Clin Oncol 2010; 136: 427-435.
28. Younis T, Haché KD, Rayson D, et al: Survivin and COX-2 expression in male breast carcinoma. Breast 2009; 18: 228-232.
29. Maxia C, Perra MT, Demurtas P, et al: Relationship between the expression of cyclooxygenase-2 and survivin in primary pterygium. Mol Vis 2009; 15: 458-463.
30. Tsujii M, Kawano S, Tsuji S, et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
31. Sengupta S, Sellers LA, Cindrova T, et al: Cyclooxygenease-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis. Cancer Res 2003; 63: 8351-8359.
32. Li W, Xu R J, Zhang HH, et al: Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma. Int J Gynecol Cancer 2006; 16: 1673-1678.
33. Eble JN, Sauter G, Epstein JE, et al (eds): World Health Organization Classification of Tumours. Pathology and Genetics of the Urinary System and Male Genital Organs. Lyon: IARC, 2004.
34. Sobin LH, Wittekind C: Urinary Bladder. International Union Against Cancer (UICC): TNM Classification of Malignant Tumors, 5th edn. New York: Wiley-Liss, 1997; pp 187-190.
35. Masunaga R, Kohno H, Dhar DK, et al: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6: 4064-4068.
36. Stravropoulos NE, Bouropoulos C, Lochim IE, et al: Prognostic significance of angiogenesis in superficial bladder cancer. Int Urol Nephrol 2004; 36: 163-167.
37. Wadhwa P, Goswami AK, Sharma SK, et al: Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol Nephrol 2005; 37: 47-53.
38. Castelao JE, Yuan JM, Gago-Dominguez M, et al: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82: 1364-1369.
39. Grubbs CJ, Lubert RA, Koki AT, et al: Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60: 5599-5602.
40. Rao KV, Detrisac CJ, Steele VE, et al: Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 1996; 17: 1435-1438.
41. Holmäng S, Cano M, Grenabo L, et al: Effect of indomethacin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced urinary tract carcinogenesis. Carcinogenesis 1995; 16: 1493-1498.
42. Okajima E, Denda A, Ozono S, et al: Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Res 1998; 58: 3028-3031.
43. Mohammed SI, Knapp DW, Bostwick DG, et al: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 5647-5650.
44. Canoglu A, Gögüs C, Beduk Y, et al: Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol 2004; 36: 401-405.
45. Reiher F, Ozer O, Pins M, et al: P53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol 2002; 167: 1469-1474.
46. Santos L, Costa C, Pereira S, et al: Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol 2003; 14: 1419-1424.
47. Thorat M, Mehrotra S, Morimiya A, et al: COX-2 expression does not correlate with microvessel density in breast cancer. Pathobiology 2009; 76: 39-44.